In the run-up to China’s annual drug price talks, scheduled for November in an update to the National Reimbursement Drug List (NRDL), a senior official at the National Healthcare Security Administration (NHSA) made a rare public appearance to defend the agency’s tough price-cutting stance, which could dampen pharma companies’ hopes of negotiating a premium for their innovative drugs.
Chinese Public Healthcare Insurance Official Defends Steep Drug Price Cuts
China’s National Healthcare Security Administration (NHSA) seems determined to require pharma firms to comply with the agency’s request to cap the prices of innovative drugs, according to a senior official directly involved in annual price negotiations.
More from China
• By
A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.
• By
While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.
• By
The main 2025 policy priorities for China's government as outlined in an annual report will include the strengthening of commercial insurance for innovative drugs and opening up cell and gene therapy and the hospital sector to foreign investment.
• By
US pharma leadership is painting its mission, particularly its goal to end Medicare price controls, as patriotic and essential to America’s global dominance over China, a move that seems designed to align with President Trump’s priorities.
More from Asia
• By
A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.
• By
Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.
• By
While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.